Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)
Total
Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning Balance at Dec. 31, 2019 $ (24,078,857) $ 13 $ 344,029 $ 31,259,365 $ (55,682,264)
Beginning Balance, Shares at Dec. 31, 2019   13,000 34,402,943    
Share-based compensation from issuance of options and compensation-based warrants 25,614     25,614  
Exercise of stock options 71,596   $ 8,177 63,419  
Exercise of stock options, Shares     817,732    
Net Income/(Loss) 5,438,024       5,438,024
Ending Balance at Mar. 31, 2020 (18,543,623) $ 13 $ 352,206 31,348,398 (50,244,240)
Ending Balance, Shares at Mar. 31, 2020   13,000 35,220,675    
Beginning Balance at Dec. 31, 2019 (24,078,857) $ 13 $ 344,029 31,259,365 (55,682,264)
Beginning Balance, Shares at Dec. 31, 2019   13,000 34,402,943    
Share-based compensation from issuance of options and compensation-based warrants 189,938        
Net Income/(Loss) (3,401,075)        
Ending Balance at Sep. 30, 2020 (21,721,521) $ 13 $ 358,499 37,003,306 (59,083,339)
Ending Balance, Shares at Sep. 30, 2020   13,000 35,849,961    
Beginning Balance at Mar. 31, 2020 (18,543,623) $ 13 $ 352,206 31,348,398 (50,244,240)
Beginning Balance, Shares at Mar. 31, 2020   13,000 35,220,675    
Share-based compensation from issuance of options and compensation-based warrants 155,186     155,186  
Exercise of stock options 19,200   $ 6,293 12,907  
Exercise of stock options, Shares     629,286    
Option grants for investment in subsidiaries 5,477,677     5,477,677  
Net Income/(Loss) (3,411,517)       (3,411,517)
Ending Balance at Jun. 30, 2020 (16,303,077) $ 13 $ 358,499 36,994,168 (53,655,757)
Ending Balance, Shares at Jun. 30, 2020   13,000 35,849,961    
Share-based compensation from issuance of options and compensation-based warrants 9,138     9,138  
Net Income/(Loss) (5,427,582)       (5,427,582)
Ending Balance at Sep. 30, 2020 (21,721,521) $ 13 $ 358,499 37,003,306 (59,083,339)
Ending Balance, Shares at Sep. 30, 2020   13,000 35,849,961    
Beginning Balance at Dec. 31, 2020 (28,734,073) $ 13 $ 358,499 37,139,854 (66,232,439)
Beginning Balance, Shares at Dec. 31, 2020   13,000 35,850,089    
Share-based compensation from issuance of options and compensation-based warrants 102,000     102,000  
Shares issued upon reverse split to avoid fractional shares     $ 19 (19)  
Shares issued upon reverse split to avoid fractional shares, Shares     1,793    
Conversion of note payable to shares 476,036   $ 15,868 460,168  
Conversion of note payable to shares, Shares     1,586,786    
Net Income/(Loss) (8,221,174)       (8,221,174)
Ending Balance at Mar. 31, 2021 (36,377,211) $ 13 $ 374,386 37,702,003 (74,453,613)
Ending Balance, Shares at Mar. 31, 2021   13,000 37,438,668    
Beginning Balance at Dec. 31, 2020 (28,734,073) $ 13 $ 358,499 37,139,854 (66,232,439)
Beginning Balance, Shares at Dec. 31, 2020   13,000 35,850,089    
Share-based compensation from issuance of options and compensation-based warrants 450,320        
Purchase of Agribody Technologies, Inc $ 5,000,000        
Purchase of Agribody Technologies, Inc, Shares 830,526        
Net Income/(Loss) $ (33,980,426)        
Ending Balance at Sep. 30, 2021 (53,368,415) $ 0 $ 400,630 46,443,820 (100,212,865)
Ending Balance, Shares at Sep. 30, 2021   0 40,063,068    
Beginning Balance at Mar. 31, 2021 (36,377,211) $ 13 $ 374,386 37,702,003 (74,453,613)
Beginning Balance, Shares at Mar. 31, 2021   13,000 37,438,668    
Share-based compensation from issuance of options and compensation-based warrants 154,244     154,244  
Exercise of stock options 9,344   $ 610 8,734  
Exercise of stock options, Shares     60,978    
Purchase of Agribody Technologies, Inc 5,000,000   $ 8,305 4,991,695  
Purchase of Agribody Technologies, Inc, Shares     830,526    
Conversion of Series B Preferred to Common, Shares   (13,000) 1,181,819    
Conversion of Series B Preferred to Common   $ (13) $ 11,818 (11,805)  
Conversion of convertible notes, Shares     53,723    
Conversion of convertible notes 308,889   $ 537 308,352  
Issuance of common stock for cash 3,100,000   $ 4,960 3,095,040  
Issuance of common stock for cash, Shares     496,000    
Net Income/(Loss) (14,078,302)       (14,078,302)
Ending Balance at Jun. 30, 2021 (41,883,036) $ 0 $ 400,616 46,248,263 (88,531,915)
Ending Balance, Shares at Jun. 30, 2021   0 40,061,714    
Share-based compensation from issuance of options and compensation-based warrants 194,076     194,076  
Exercise of stock options 1,495   $ 14 1,481  
Exercise of stock options, Shares     1,354    
Net Income/(Loss) (11,680,950)       (11,680,950)
Ending Balance at Sep. 30, 2021 $ (53,368,415) $ 0 $ 400,630 $ 46,443,820 $ (100,212,865)
Ending Balance, Shares at Sep. 30, 2021   0 40,063,068